Correlation of H2 O2 , pH and nitrite/nitrate in exhaled breath condensate and systemic inflammatory parameters during and after acute COPD exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 349s Year: 2005
pH in exhaled breath condensate of patients with stable COPD: associations with disease severity and pulmonary function tests Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009
The clinical significance of growth factors measurement in exhaled breath condensates (EBC) among patients with interstitial lung diseases Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
Correlation between lung function and exhaled breath condensate biomarkers of inflammation in pulmonary diseases Source: Annual Congress 2009 - Lung function in adults and children Year: 2009
Nitrite concentration in exhaled breath condensate correlates with markers of lung overdistension in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 317s Year: 2004
pH in exhaled breath condensate of patients with inflammatory airway diseases Source: Eur Respir J 2003; 22: Suppl. 45, 240s Year: 2003
pH in expired breath condensate of patients with inflammatory airway diseases Source: Eur Respir J 2001; 18: Suppl. 33, 248s Year: 2001
Relationship of inflamamatory markers in blood and exhaled breath condensate in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 283s Year: 2006
Exhaled breath condensate biomarkers in COPD Source: Eur Respir J 2008; 32: 472-486 Year: 2008
Assessment of exhaled breath condensate pH in asthma and COPD patients with exacerbation Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010
Correlation of ventilatory parameters and disease severity with detection rate of cytokeratins in exhaled breath condensate Source: Eur Respir J 2005; 26: Suppl. 49, 557s Year: 2005
Myeloperoxidase in exhaled breath condensate reflects the status of lung parenchyma during the exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 54s Year: 2005
Periostin in exhaled breath condensate as a biomarker of different severe asthma phenotypes. Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017
The relationship between CT assessed lung damage, and inflammatory markers in exhaled breath condensate of cystic fibrosis patients Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007
Exhaled breath condensate for evaluation of inflammation in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 35s Year: 2006
The value of exhaled breath condensate ‘pH‘ to evaluate the severity of disease and the response to treatment in patients with community acquired pneumonia Source: Annual Congress 2011 - Assessment of severity and predictors of outcomes in community-acquired pneumonia Year: 2011
Markers of airway diseases in exhaled breath condensate and their clinical value Source: School Course 2013 - Monitoring of asthma, COPD and other airway diseases Year: 2013
Inflammatory cytokines in exhaled breath condensate (EBC) of exacerbated COPD patients Source: Annual Congress 2008 - Inflammatory biomarkers Year: 2008
Exhaled breath condensate pH is low in patients with respiratory failure Source: Eur Respir J 2006; 28: Suppl. 50, 789s Year: 2006
Prediction of CF exacerbations by FeNO and non-invasive inflammatory markers in exhaled breath condensate Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation Year: 2008